BCM
CADL icon

Boreal Capital Management’s Candel Therapeutics CADL Stock Holding History

Boreal Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.4K Sell
8,000
-8,000
-50% -$60.4K 0.06% 158
2026
Q1 		$78.4K Hold
16,000
– – 0.06% 166
2025
Q4 		$90.4K Hold
16,000
– – 0.07% 165
2025
Q3 		$81.6K Hold
16,000
– – 0.07% 181
2025
Q2 		$81K Buy
+16,000
New +$82.3K 0.07% 181

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boreal Capital Management's CADL Position: Q2 2026 in Review

Boreal Capital Management reduced its Candel Therapeutics (CADL) stake by 50% in Q2 2026, selling an estimated $60.4K and leaving 8,000 shares worth $82.4K. The position accounts for 0.06% of the portfolio, ranked #158.

Boreal Capital Management first reported a position in CADL in Q2 2025 and has held it in 5 quarters since. The position peaked at $90.4K in Q4 2025. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Boreal Capital Management held 8,000 shares of Candel Therapeutics worth $82.4K as of Q2 2026.
  • Boreal Capital Management sold 8,000 Candel Therapeutics shares in Q2 2026, an estimated $60.4K.
  • Candel Therapeutics made up 0.06% of Boreal Capital Management's portfolio in Q2 2026, its #158 holding.
  • Boreal Capital Management first reported a position in Candel Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Boreal Capital Management's Candel Therapeutics position peaked at $90.4K in Q4 2025.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Boreal Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.